Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
399 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Psoriasis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Psoriasis - Pipeline Review, H2 2014', provides an overview of the Psoriasis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 7 Psoriasis Overview 8 Therapeutics Development 9 Psoriasis - Therapeutics under Development by Companies 11 Psoriasis - Therapeutics under Investigation by Universities/Institutes 19 Psoriasis - Pipeline Products Glance 21 Psoriasis - Products under Development by Companies 25 Psoriasis - Products under Investigation by Universities/Institutes 33 Psoriasis - Companies Involved in Therapeutics Development 34 Psoriasis - Therapeutics Assessment 123 Drug Profiles 140 Psoriasis - Recent Pipeline Updates 316 Psoriasis - Dormant Projects 370 Psoriasis - Discontinued Products 375 Psoriasis - Product Development Milestones 376 Appendix 383
List of Tables Number of Products under Development for Psoriasis, H2 2014 24 Number of Products under Development for Psoriasis - Comparative Analysis, H2 2014 25 Number of Products under Development by Companies, H2 2014 27 Number of Products under Development by Companies, H2 2014 (Contd..1) 28 Number of Products under Development by Companies, H2 2014 (Contd..2) 29 Number of Products under Development by Companies, H2 2014 (Contd..3) 30 Number of Products under Development by Companies, H2 2014 (Contd..4) 31 Number of Products under Development by Companies, H2 2014 (Contd..5) 32 Number of Products under Development by Companies, H2 2014 (Contd..6) 33 Number of Products under Investigation by Universities/Institutes, H2 2014 35 Comparative Analysis by Late Stage Development, H2 2014 36 Comparative Analysis by Clinical Stage Development, H2 2014 37 Comparative Analysis by Early Stage Development, H2 2014 38 Comparative Analysis by Unknown Stage Development, H2 2014 39 Products under Development by Companies, H2 2014 40 Products under Development by Companies, H2 2014 (Contd..1) 41 Products under Development by Companies, H2 2014 (Contd..2) 42 Products under Development by Companies, H2 2014 (Contd..3) 43 Products under Development by Companies, H2 2014 (Contd..4) 44 Products under Development by Companies, H2 2014 (Contd..5) 45 Products under Development by Companies, H2 2014 (Contd..6) 46 Products under Development by Companies, H2 2014 (Contd..7) 47 Products under Investigation by Universities/Institutes, H2 2014 48 Psoriasis - Pipeline by 4SC AG, H2 2014 49 Psoriasis - Pipeline by Acceleron Pharma, Inc., H2 2014 50 Psoriasis - Pipeline by Addex Therapeutics Ltd, H2 2014 51 Psoriasis - Pipeline by Advinus Therapeutics Ltd., H2 2014 52 Psoriasis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H2 2014 53 Psoriasis - Pipeline by AlbireoPharma, H2 2014 54 Psoriasis - Pipeline by Allozyne, Inc., H2 2014 55 Psoriasis - Pipeline by Almirall, S.A., H2 2014 56 Psoriasis - Pipeline by Amgen Inc., H2 2014 57 Psoriasis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2014 58 Psoriasis - Pipeline by AnaptysBio, Inc., H2 2014 59 Psoriasis - Pipeline by Apexigen, Inc., H2 2014 60 Psoriasis - Pipeline by ApoPharma Inc., H2 2014 61 Psoriasis - Pipeline by Argos Therapeutics, Inc., H2 2014 62 Psoriasis - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 63 Psoriasis - Pipeline by Basilea Pharmaceutica AG, H2 2014 64 Psoriasis - Pipeline by Bionomics Limited, H2 2014 65 Psoriasis - Pipeline by Brickell Biotech, Inc., H2 2014 66 Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H2 2014 67 Psoriasis - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2014 68 Psoriasis - Pipeline by Celgene Corporation, H2 2014 69 Psoriasis - Pipeline by Cellceutix Corporation, H2 2014 70 Psoriasis - Pipeline by Celltrion, Inc., H2 2014 71 Psoriasis - Pipeline by ChironWells GmbH, H2 2014 72 Psoriasis - Pipeline by Compugen Ltd., H2 2014 73 Psoriasis - Pipeline by Covagen AG, H2 2014 74 Psoriasis - Pipeline by Creabilis SA, H2 2014 75 Psoriasis - Pipeline by Crescendo Biologics Limited, H2 2014 76 Psoriasis - Pipeline by CTI BioPharma Corp., H2 2014 77 Psoriasis - Pipeline by Delenex Therapeutics AG, H2 2014 78 Psoriasis - Pipeline by Echo Therapeutics, Inc., H2 2014 79 Psoriasis - Pipeline by Effimune SAS, H2 2014 80 Psoriasis - Pipeline by Eli Lilly and Company, H2 2014 81 Psoriasis - Pipeline by Farmacija d.o.o. Tuzla, H2 2014 82 Psoriasis - Pipeline by Fibrocell Science, Inc., H2 2014 83 Psoriasis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2014 84 Psoriasis - Pipeline by Gem Pharmaceuticals, LLC, H2 2014 85 Psoriasis - Pipeline by Gene Signal International SA, H2 2014 86 Psoriasis - Pipeline by Genentech, Inc., H2 2014 87 Psoriasis - Pipeline by GlaxoSmithKline plc, H2 2014 88 Psoriasis - Pipeline by GliaCure Inc., H2 2014 89 Psoriasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 90 Psoriasis - Pipeline by Hydra Biosciences, Inc., H2 2014 91 Psoriasis - Pipeline by Immune Response BioPharma, Inc., H2 2014 92 Psoriasis - Pipeline by Johnson & Johnson, H2 2014 93 Psoriasis - Pipeline by Kadmon Corporation, LLC, H2 2014 94 Psoriasis - Pipeline by KAHR medical Ltd., H2 2014 95 Psoriasis - Pipeline by Kainos Medicine, Inc., H2 2014 96 Psoriasis - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2014 97 Psoriasis - Pipeline by Kangstem Holdings Co., Ltd., H2 2014 98 Psoriasis - Pipeline by Kinex Pharmaceuticals, LLC, H2 2014 99 Psoriasis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H2 2014 100 Psoriasis - Pipeline by LegoChem Biosciences, Inc, H2 2014 101 Psoriasis - Pipeline by LEO Pharma A/S, H2 2014 102 Psoriasis - Pipeline by Lupin Limited, H2 2014 103 Psoriasis - Pipeline by Lycera Corp., H2 2014 104 Psoriasis - Pipeline by MediGene AG, H2 2014 105 Psoriasis - Pipeline by NicOx S.A., H2 2014 106 Psoriasis - Pipeline by Nimbus Discovery, LLC, H2 2014 107 Psoriasis - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2014 108 Psoriasis - Pipeline by Novartis AG, H2 2014 109 Psoriasis - Pipeline by Oncobiologics, Inc., H2 2014 110 Psoriasis - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 111 Psoriasis - Pipeline by OPKO Health, Inc., H2 2014 112 Psoriasis - Pipeline by Panacea Biotec Limited, H2 2014 113 Psoriasis - Pipeline by Pfizer Inc., H2 2014 114 Psoriasis - Pipeline by Pharis Biotec GmbH, H2 2014 115 Psoriasis - Pipeline by Pharmedartis GmbH, H2 2014 116 Psoriasis - Pipeline by Phenex Pharmaceuticals AG, H2 2014 117 Psoriasis - Pipeline by Pieris AG, H2 2014 118 Psoriasis - Pipeline by PinCell srl, H2 2014 119 Psoriasis - Pipeline by Piramal Enterprises Limited, H2 2014 120 Psoriasis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2014 121 Psoriasis - Pipeline by PurGenesis Technologies Inc., H2 2014 122 Psoriasis - Pipeline by RestorGenex Corporation, H2 2014 123 Psoriasis - Pipeline by Rigel Pharmaceuticals, Inc., H2 2014 124 Psoriasis - Pipeline by Salix Pharmaceuticals Ltd., H2 2014 125 Psoriasis - Pipeline by Sareum Holdings plc, H2 2014 126 Psoriasis - Pipeline by Selvita SA, H2 2014 127 Psoriasis - Pipeline by Sigmoid Pharma Limited, H2 2014 128 Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2014 129 Psoriasis - Pipeline by SWITCH Biotech LLC, H2 2014 130 Psoriasis - Pipeline by Synta Pharmaceuticals Corp., H2 2014 131 Psoriasis - Pipeline by Telormedix SA, H2 2014 132 Psoriasis - Pipeline by Uni-Bio Science Group Ltd., H2 2014 133 Psoriasis - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 134 Psoriasis - Pipeline by Virobay Inc., H2 2014 135 Psoriasis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2014 136 Psoriasis - Pipeline by Welichem Biotech Inc., H2 2014 137 Assessment by Monotherapy Products, H2 2014 138 Assessment by Combination Products, H2 2014 139 Number of Products by Stage and Target, H2 2014 141 Number of Products by Stage and Mechanism of Action, H2 2014 146 Number of Products by Stage and Route of Administration, H2 2014 152 Number of Products by Stage and Molecule Type, H2 2014 154 Psoriasis Therapeutics - Recent Pipeline Updates, H2 2014 331 Psoriasis - Dormant Projects, H2 2014 385 Psoriasis - Discontinued Products, H2 2014 390
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
